Informuta's approach

Leveraging the power of ML

Informuta is leveraging its next-generation sequencing- and ML-powered proprietary technology to revolutionize infectious disease detection. RESISENSE™ is a diagnostic platform powered by advanced machine learning (ML) models that analyze DNA sequencing data to predict both current antibiotic resistance and the likelihood of future resistance acquisition. This method works with all species, including various bacteria, fungi, and viruses, detecting emerging resistance mechanisms that other tests might miss. By identifying mutational signatures in bacterial DNA, RESISENSE™ provides clinicians with actionable insights for precision treatment, ensuring a comprehensive and proactive approach to managing antibiotic resistance.

Core Technology

RESISENSE™

RESISENSE™ is based on proprietary ML models that analyze entire bacterial genomes for mutational signatures. These signatures, which act as 'fingerprints' of errors left behind by cellular processes, are highly specific patterns of mutations that inform model predictions. RESISENSE™ can detect both current resistance and predict future resistance acquisition. This comprehensive approach ensures timely and accurate guidance for clinicians, ultimately improving patient outcomes and combating the growing threat of antibiotic resistance.

Detection of Current Resistance

RESISENSE™ utilizes mutational signatures to accurately detect current antibiotic resistance in a species-independent and resistance mechanism-independent manner. Unlike other technologies that screen for specific known mutations, RESISENSE™ detects resistance without reliance on these known changes. This is crucial because while other methods can identify known mutations, the nature of antibiotic resistance means that bacteria will eventually evolve into unknown forms that these methods cannot detect. RESISENSE™ overcomes this limitation, offering comprehensive genomic antibiotic susceptibility testing (g-AST) that is both rapid and reliable.

Prediction of Future Resistance

Beyond detecting existing resistance, RESISENSE™ is pioneering in its ability to predict the future acquisition of resistance. By identifying mutational signatures linked to rapid multidrug resistance (MDR) acquisition, RESISENSE™ can forecast which infections are likely to develop resistance over time. This predictive capability is a significant advancement in the field of infectious disease diagnostics, providing clinicians with the foresight needed to tailor treatment plans proactively and mitigate the spread of resistant infections.